New HIV Drug Combination Shows Superiority


Dolutegravir/abacavir shows a solid safety profile and a high barrier to resistance.

A new drug combination showed promising results in treatment-naïve women with HIV, researchers reported today at IDWeek 2016 in New Orleans, LA.

ViiV Healthcare investigator Debbie Hagins, MD, and colleagues, noted that a fixed dose combination of dolutegravir/abacavir showed “good tolerability and a high barrier to resistance.”

Their study, called ARIA, is an international open-label comparison of the new combination versus atazanavir plus disoproxil fumarate/emtricitabine. In all 495 women were randomized and treated.

Their median age was 37, and about half were white and half of African heritage.

The new combination was superior to the comparison product, with 82% of women administered the new drug achieving HIV-1 RNA of less than 50 c/mL compared with 71% on the older regimen.

These findings applied across race subgroups, and the new drug had fewer drug-related adverse events, the researchers said.

They concluded the new combination “demonstrated superior efficacy and a favorable safety” compared with the older drug combination in treatment naïve women after 48 weeks of treatment.

Related Videos
Pharmacist holding medicine box in pharmacy drugstore. | Image Credit: I Viewfinder -
Pharmacy Drugstore Checkout Cashier Counter | Image Credit: Gorodenkoff -
Medicine tablets on counting tray with counting spatula at pharmacy | Image Credit: sutlafk -
Capsules medicine and white medicine bottles on table | Image Credit: Satawat -
Human cell or Embryonic stem cell microscope background | Image Credit: Anusorn -
Concept of health care, pharmaceutical business, drug prices, pharmacy, medicine and economics | Image Credit: Oleg -
Biosimilar pharmaceutical drug bottle on blue background. | Image Credit: Carl -
Pharmaceutical manufacture background with glass bottles with clear liquid on automatic conveyor line. | Image Credit: wacomka -
Bottle and scattered pills on color background, top view | Image Credit: New Africa -
pharmacy | Image Credit: Diego Cervo -
© 2024 MJH Life Sciences

All rights reserved.